UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000006307
Receipt number R000007472
Scientific Title Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.
Date of disclosure of the study information 2011/09/08
Last modified on 2017/01/13 13:50:37

No. Disposal Last modified on Item of update
1 Insert 2011/09/08 10:32:33
2 Update 2011/10/17 10:18:37 Organization1
Address1
Tel1
Email1
Institutions
3 Update 2011/10/17 10:52:59 Institutions
4 Update 2011/10/24 15:20:16 Institutions
5 Update 2011/10/25 11:52:25 Institutions
6 Update 2011/11/02 10:42:07 Institutions
7 Update 2011/11/11 14:24:50 Institutions
8 Update 2011/12/01 09:39:31 Institutions
9 Update 2012/01/06 09:41:39 Institutions
10 Update 2012/01/11 16:48:39 Institutions
11 Update 2012/01/12 11:36:28 Institutions
12 Update 2012/01/24 14:38:15 Institutions
13 Update 2012/01/31 15:49:49 Email
14 Update 2012/04/18 10:56:33 Institutions
15 Update 2012/09/10 09:43:13 Institutions
16 Update 2013/03/08 10:29:32 Institutions
17 Update 2013/04/08 10:09:30 Institutions
18 Update 2013/08/14 15:38:56 UMIN ID1
19 Update 2013/08/14 15:42:31 Recruitment status
20 Update 2014/03/10 09:10:18 Email
Last name of contact person
Last name of contact person
Email
21 Update 2015/05/22 08:08:42 Email
Email
Email
22 Update 2016/02/24 19:11:41 Acronym
Acronym
23 Update 2016/09/11 16:45:14 Name of primary person or sponsor
Organization
24 Update 2016/09/11 16:47:00 Recruitment status
Publication of results
Results
25 Update 2017/01/13 13:47:26 Public title
26 Update 2017/01/13 13:47:44 Acronym
27 Update 2017/01/13 13:49:05 Anticipated trial start date
28 Update 2017/01/13 13:50:37 Recruitment status
URL related to results and publications